FY2025 EPS Estimates for AxoGen Lowered by Cantor Fitzgerald

AxoGen, Inc. (NASDAQ:AXGN) – Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of AxoGen in a report issued on Wednesday, February 26th. Cantor Fitzgerald analyst R. Osborn now forecasts that the medical equipment provider will post earnings of $0.07 per share for the year, down from their previous estimate of $0.19. The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share.

Separately, Canaccord Genuity Group upped their target price on shares of AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday.

AxoGen Stock Down 0.2 %

Shares of AXGN stock opened at $19.43 on Friday. AxoGen has a 12-month low of $5.55 and a 12-month high of $21.00. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The firm has a fifty day moving average of $17.66 and a 200-day moving average of $14.99. The company has a market capitalization of $855.08 million, a price-to-earnings ratio of -60.72 and a beta of 1.00.

Institutional Trading of AxoGen

A number of institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC grew its position in AxoGen by 10.2% in the fourth quarter. First Light Asset Management LLC now owns 4,506,795 shares of the medical equipment provider’s stock valued at $74,272,000 after purchasing an additional 416,499 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of AxoGen by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider’s stock worth $14,170,000 after buying an additional 31,612 shares during the last quarter. Driehaus Capital Management LLC grew its holdings in shares of AxoGen by 166.0% in the 4th quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider’s stock valued at $15,729,000 after acquiring an additional 595,579 shares in the last quarter. State Street Corp increased its position in shares of AxoGen by 11.9% in the third quarter. State Street Corp now owns 896,674 shares of the medical equipment provider’s stock valued at $12,571,000 after acquiring an additional 95,051 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in AxoGen by 13.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 772,752 shares of the medical equipment provider’s stock worth $12,735,000 after acquiring an additional 91,984 shares in the last quarter. Institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.